期刊文献+

胆总管十二指肠吻合术后42年再发胆管癌(英文) 被引量:1

Cholangiocarcinoma Developing 42-year after Choledochoduodenostomy
下载PDF
导出
摘要 胆总管十二指肠吻合术是常用的胆肠吻合方式,曾被公认为是"无害"的手术方式。但近数年来,已有相关报道胆总管十二指肠吻合术后多年可能再发胆管癌,并认为其是继胆管炎以外最严重的并发症。本文报道了1例因肝内外胆管结石行胆总管十二指肠吻合术后42年再发胆管癌的患者,并对有关文献进行回顾与总结,并推荐对施行胆肠吻合术,尤其对于术后多次伴发胆管炎的患者,做常规随访是防止严重并发症的有效方式。 Anastomosis between the biliary tract and the intestinal tract has been, and is, a relatively common procedure. Aside from cholangitis secondary to anastomotic stricture, it is generally regarded as innocuous. However, the correlation between biliary-enteric surgical drainage and the late development of cholangiocarcino- ma of the biliary tract has recently been documented, and has become a serious issue today. It is reported that a case of a 68-year-old woman had developed a cholangiocarcinoma 42-year after choledochoduodenostomy because of choledocholithiasis. Descriptions of cholangiocarcinoma arising after biliary-enteric drainage procedures for benign disease are reviewed. These biliary epithelial changes presumably induced by chronic inflammation due to the reflux of intestinal contents and bile stasis may be responsible for the carcinogenesis. Experimental, clini- cal, and epidemiological data are available to support the hypothesis that a link between cholangiocarcinoma and biliary drainage procedures. Chronic inflammatory changes consequent to biliary-enteric drainage should be closely monitored for the late development of biliary tract malignancies.
出处 《中国肿瘤外科杂志》 CAS 2010年第3期166-169,共4页 Chinese Journal of Surgical Oncology
  • 相关文献

参考文献1

二级参考文献6

共引文献14

同被引文献19

  • 1Palel T, Medscape. Cholangiocarcinoma: controversies and challen ges [J]. Nat Rex, Gastroenterol HepatoI,2011,8(4) : 189-200.
  • 2Welzel TM,McGlynn KA,Hsing AW,e~ al. Impact of elassifi cation of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra-and extrahepatic cholangiocarcinoma in the United States [J]. J Natl Cancer Inst,2006,98(12):873-875.
  • 3Edge SB, Byrd DR. Compton CC, et al. AJCC Cancer Staging Manual[ M]. 7th edition . Germany : Springer, 20119 : 191-234.
  • 4J emal A, Siegel R. Ward E, et al. Cancer statistics, 2008[J]. CA (Cancer J Clin,2008,58(2) :71-96.
  • 5Friman S. Cholangiocarcinoma current treatment options [J]. Scand J Surg,2011.1(10(1 ) :30-34.
  • 6Nathan H, Aloia TA, Vauthey JN, et al. A proposed staging system for intrahepatic cholangiocarcinoma [J]. Ann Surg On- co1.2009,16(1) : 14- 22.
  • 7lsomoto H, Kobayashi S, Werneburg NW, et al. Interleukin 6 up- regulates myeloid cell leukemia-1 expression through a STAT3 pathway in cholangiocarcinoma ceils [J]. Hepatology, 2005,42 (6) :1329-1338.
  • 8Meng F,Wehhe-Janek H, Henson R,et al. Epigenetic regula- tion of mieroRNA-370 by interleukin-6 in malignant human cholangiocyt es [J ]- Oncogene, 2008,27 ( 3 ) : 378-386.
  • 9Kuroki T,Tajima Y,Kanematsu T. Hepatolithiasis and intra hepatic cholangiocareinoma: carcinogenesis based on molecular mechanisms [J].J Hepatobiliary Pancreat Surg,21105,12(6): 463-466.
  • 10Sirica AE. Cholangiocarcinoma.-molecular targeting strategies for chemoprevention andtherapy [ J]. Hepatology, 2005, 41(1):5-15.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部